Teva jumps sharply on bowel disease drug results

Teva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn’s disease, the most common forms of inflammatory bowel disease. | Read More in Front – Globes.   Read More in Israel NOWlej.